Definium Therapeutics, Inc. (DFTX)
36.16
-0.58
(-1.57%)
USD |
NASDAQ |
Sep 25, 16:00
36.28
+0.12
(+0.35%)
After-Hours: 17:17
Definium Therapeutics Research and Development Expense (Annual) : 117.66M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 117.66M |
| December 31, 2024 | 64.77M |
| December 31, 2023 | 48.96M |
| December 31, 2022 | 32.99M |
| December 31, 2021 | 32.17M |
| Date | Value |
|---|---|
| December 31, 2020 | 18.63M |
| August 31, 2019 | |
| August 31, 2018 | |
| August 31, 2017 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Enliven Therapeutics, Inc. | 85.59M |
| Cocrystal Pharma, Inc. | 5.055M |
| CNBX Pharmaceuticals, Inc. | 0.00 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 282.90M |